BioSpace News Archive

Vitro Diagnostics, Inc., dba Vitro Biopharma, announced its 3rd quarter, ended July 31st 2020, financial results of operations.

Pfizer Inc. announced that its investigational gene therapy candidate being developed to treat Duchenne muscular dystrophy received Fast Track designation from the U.S. Food and Drug Administration.

Akouos, Inc., a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, announced the appointment of Sachiyo Minegishi as chief financial officer

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced it will present multiple posters on the company’s ongoing studies in patients with facioscapulohumeral muscular dystrophy during the 25th International Congress of the World Muscle Society.

Bio-Techne Corporation announced the opening of its new Canadian office located in Toronto.

Majority of customers to see a reduced or same premium, with a $0 premium plan available in every market and virtual care offered at no cost

Chastity no signs of cancer after undergoing CAR T therapy, short for chimeric antigen receptor T-cell therapy — and is one of the youngest patients to receive this advanced cancer treatment.

CANTEL MEDICAL CORP announced that Michael Drexel has been hired as Senior Vice President and Chief Technology Officer reporting to George Fotiades, Chief Executive Officer.

VYNE Therapeutics Inc. announced that its novel ZILXI™ topical foam, 1.5% will be available on October 1, 2020 by prescription for the treatment of inflammatory lesions of rosacea in adults.

Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced it has entered into a $25.0 million senior secured term loan with MidCap Financial Trust, as agent, and Silicon Valley Bank.